key articles
Evaluation of pT2 subdivisions in the tumour-nodes-metastases staging system for prostate cancer
Wednesday, 20 August 2008 - Hong et al. (2008) evaluated the subclassifications of pT2 diseases in tumour-nodes-metastases (TNM) staging system for prostate cancer.
The authors retrospectively analysed the data of 372 patients...
Authors: Hong et al.
Management of recurrent anastomotic stenosis following radical prostatectomy using holmium laser and steroid injection
Wednesday, 20 August 2008 - Eltahawy et al. (2008) reported their experience with the management of recurrent and resistant anastomotic stenosis following radical prostatectomy (RP) using transurethral laser incision of the...
Authors: Eltahawy et al.
Testosterone for testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer
Wednesday, 20 August 2008 - Morales et al. (2008) assessed the effects of testosterone supplementation in men with testosterone deficiency syndrome (TDS) after external beam radiotherapy (EBRT) for localized prostate...
Authors: Morales et al.
Benefits and harms of prostate-specific antigen screening for prostate cancer
Tuesday, 19 August 2008 - Prostate cancer is the most common nonskin cancer in men in the United States, and prostate cancer screening has increased in recent years. In 2002, the U.S. Preventive Services Task Force concluded that...
Authors: Lin et al.
Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer
Tuesday, 19 August 2008 - Delongchamps et al. (2008) evaluated a 36-core saturation biopsy scheme on autopsied prostate glands to estimate the detection rate based on the true cancer prevalence, and to compare the cancer features...
Authors: Delongchamps et al.
Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy
Tuesday, 19 August 2008 - Although pelvic lymph node dissection (PLND) during radical prostatectomy (RP) improves staging, controversy remains concerning its indications and benefits on cancer control. Prasad et al. (2008)...
Authors: Prasad et al.
Disseminated tumor cells in bone marrow following definitive radiotherapy for intermediate or high-risk prostate cancer
Monday, 18 August 2008 - Berg et al. (2008) explored the prevalence of disseminated tumor cells (DTCs) in bone marrow (BM) of clinically progression-free prostate cancer (PC) patients at least 2 years after curatively intended...
Authors: Berg et al.
Lower urinary tract symptoms and risk of prostate cancer
Sunday, 17 August 2008 - Screening for early prostate cancer is frequently employed in the routine management of men with lower urinary tract symptoms (LUTS), but the evidence-base linking LUTS with prostate cancer is...
Authors: Martin et al.
Durable complete response to frontline docetaxel in an advanced prostate cancer patient
Friday, 15 August 2008 - Docetaxel is currently indicated for androgen-independent, metastatic prostate cancer; there is also evidence demonstrating the role of CYP1B1 in modulating the activity of the drug. Brandi et al. (2008)...
Authors: Brandi et al.
ProsCan for Men: Randomised controlled trial of a decision support intervention for men with localised prostate cancer
Friday, 15 August 2008 - Prostate cancer is the most common male cancer in the Western world but is highly heterogeneous in disease progression and outcomes. Consequently, the most substantial morbidity may actually arise from...
Authors: Chambers et al.
